Bessemer Group Inc. Acquires 54,917 Shares of Danaher Co. (NYSE:DHR)

Bessemer Group Inc. increased its holdings in shares of Danaher Co. (NYSE:DHR) by 2.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,739,315 shares of the conglomerate’s stock after acquiring an additional 54,917 shares during the quarter. Danaher comprises 1.5% of Bessemer Group Inc.’s portfolio, making the stock its 10th biggest holding. Bessemer Group Inc. owned 0.39% of Danaher worth $484,392,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the stock. Guggenheim Capital LLC boosted its stake in Danaher by 60.9% in the 4th quarter. Guggenheim Capital LLC now owns 48,490 shares of the conglomerate’s stock valued at $7,441,000 after purchasing an additional 18,350 shares during the period. Ellevest Inc. boosted its stake in Danaher by 74.6% in the 1st quarter. Ellevest Inc. now owns 632 shares of the conglomerate’s stock valued at $87,000 after purchasing an additional 270 shares during the period. Valeo Financial Advisors LLC boosted its stake in Danaher by 11.7% in the 1st quarter. Valeo Financial Advisors LLC now owns 7,555 shares of the conglomerate’s stock valued at $1,101,000 after purchasing an additional 791 shares during the period. Windsor Group LTD boosted its stake in Danaher by 10.6% in the 1st quarter. Windsor Group LTD now owns 2,391 shares of the conglomerate’s stock valued at $331,000 after purchasing an additional 230 shares during the period. Finally, Gateway Investment Advisers LLC boosted its stake in Danaher by 7.6% in the 1st quarter. Gateway Investment Advisers LLC now owns 6,960 shares of the conglomerate’s stock valued at $963,000 after purchasing an additional 490 shares during the period. 77.67% of the stock is currently owned by institutional investors and hedge funds.

In related news, Director Linda P. Hefner sold 2,754 shares of the company’s stock in a transaction dated Monday, July 27th. The stock was sold at an average price of $197.00, for a total transaction of $542,538.00. Following the sale, the director now owns 32,749 shares in the company, valued at approximately $6,451,553. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Daniel L. Comas sold 100,032 shares of the company’s stock in a transaction dated Monday, July 27th. The shares were sold at an average price of $194.56, for a total value of $19,462,225.92. Following the sale, the executive vice president now owns 134,933 shares in the company, valued at approximately $26,252,564.48. The disclosure for this sale can be found here. In the last three months, insiders sold 427,955 shares of company stock valued at $82,882,475. Insiders own 11.70% of the company’s stock.

DHR traded down $2.04 on Wednesday, reaching $200.01. The stock had a trading volume of 2,421,200 shares, compared to its average volume of 3,156,616. Danaher Co. has a fifty-two week low of $119.60 and a fifty-two week high of $207.66. The firm has a 50-day moving average of $189.55 and a 200-day moving average of $164.34. The company has a current ratio of 2.20, a quick ratio of 1.74 and a debt-to-equity ratio of 0.68. The company has a market capitalization of $142.32 billion, a price-to-earnings ratio of 44.30, a price-to-earnings-growth ratio of 3.25 and a beta of 0.95.

Danaher (NYSE:DHR) last issued its earnings results on Thursday, July 23rd. The conglomerate reported $1.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.09 by $0.35. The business had revenue of $5.30 billion during the quarter, compared to analysts’ expectations of $5.01 billion. Danaher had a return on equity of 11.88% and a net margin of 17.73%. The business’s revenue for the quarter was up 2.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.09 EPS. Sell-side analysts anticipate that Danaher Co. will post 5.42 EPS for the current fiscal year.

Several research firms recently issued reports on DHR. Royal Bank of Canada boosted their price target on Danaher from $205.00 to $218.00 and gave the company an “outperform” rating in a research note on Friday, July 24th. Robert W. Baird upped their target price on Danaher from $163.00 to $205.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. Bank of America upped their target price on Danaher from $181.00 to $215.00 and gave the company a “buy” rating in a research report on Monday, July 20th. UBS Group upped their target price on Danaher from $176.00 to $233.00 and gave the company a “buy” rating in a research report on Monday, July 27th. Finally, Stifel Nicolaus upped their target price on Danaher from $170.00 to $210.00 and gave the company a “hold” rating in a research report on Friday, July 24th. Two analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $197.73.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments; Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.

Featured Article: Strangles

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.